Browsing Clinical Studies by author "Marsden,"
Now showing items 21-40 of 72
-
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo, SP; Larkin, J; Sosman, JA; Lebbé, C; Brady, B; et al. (2017-01)Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a ... -
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
Farag, S; van Coevorden, F; Sneekes, E; Grunhagen, DJ; Reyners, AKL; et al. (2017-11)Objective Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.Methods Patients registered in the Dutch GIST Registry (DGR) ... -
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim, JS; Sundar, R; Chénard-Poirier, M; Lopez, J; Yap, TA (2017-01)The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ... -
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda, S; Negrier, S; Casper, J; Porta, C; Schmidinger, M; et al. (2017-03)Introduction Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on treatment; ... -
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; et al. (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to ... -
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
Boon, E; van der Graaf, WTA; Gelderblom, H; Tesselaar, MET; van Es, RJJ; et al. (2017-01)Background There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck.Methods All records of patients older than 16 years diagnosed with ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
Davidson, M; Chau, I; Cunningham, D; Khabra, K; Iveson, T; et al. (2017-08)Aim To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.Methods Individual patient data were pooled from three randomised phase III ... -
In Reply.
Khan, K; Cunningham, D; Aitken, K; Rao, S (2017-11) -
Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).
Harrington, K; Hall, E; Hawkins, M; Henry, A; MacKay, R; et al. (2017-11) -
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly, A; Larkin, J (2017-03)Introduction In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents ... -
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir, H; Kis, L; Ljungman, P; Larkin, J; Kefford, R; et al. (2017-07) -
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby, T; Hurt, CN; Falk, S; Gollins, S; Staffurth, J; et al. (2017-03)Background The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and ... -
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti, GV; Gaafar, R; Nowak, AK; Reck, M; Tsao, AS; et al. (2017-09)Malignant pleural mesothelioma (MPM) is a rare but aggressive disease: median survival is 6 to 9 months if untreated. Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median ... -
Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.
Tokaca, N; Barth, S; O'Brien, M; Bhosle, J; Fotiadis, N; et al. (2018-01)Introduction In the era of biomarker-driven systemic therapy for advanced NSCLC, the role of routine repeated biopsies for decision making outside EGFR-mutant disease remains unproven. We report our center's experience of ... -
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.
Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; et al. (2017-09)This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ... -
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated ... -
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson, D; Cunningham, D; Nankivell, M; Blazeby, JM; Griffin, SM; et al. (2017-09)Background Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant ... -
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl, A; Cunningham, D; Counsell, N; Hawkes, EA; Qian, W; et al. (2017-07)Background There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized ... -
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár, A; Jones, RL; Stacchiotti, S; Gelderblom, H; Guida, M; et al. (2017-01)Background Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy ... -
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs, Z; Messiou, C; Wong, HH; Hatcher, H; Miah, A; et al. (2017-04)Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of ...